Literature DB >> 7634543

Renal disease and patient survival in light chain deposition disease.

C Pozzi1, G B Fogazzi, G Banfi, E H Strom, C Ponticelli, F Locatelli.   

Abstract

We evaluated retrospectively the presenting clinical features, response to treatment and clinical course of 19 patients with LCDD, 11 of whom had multiple myeloma. At presentation, renal insufficiency was present in 18 patients and proteinuria in 16. Renal biopsy revealed typical LCDD in 16 patients, while in the remaining three LCDD was associated with other abnormal tissue deposits. Extrarenal signs were observed in 12 patients (63%), with the liver, heart and peripheral nerves being the most frequently involved organs. After diagnosis, 18 patients underwent therapy: 2 received steroids alone and 16 were treated with steroids and cytotoxic drugs; 7 patients also underwent plasma exchange. At the end of the first month of treatment renal function improved in 5 patients, worsened in 5 and remained unchanged in 8. All but 3 of the patients continued treatment beyond the first month: 7 patients developed end-stage renal disease, 5 an improvement and 4 a worsening in renal function. No effect on proteinuria was observed. Extrarenal symptoms developed in 4 previously unaffected patients and in 3 others they extended to more organs. Sixteen patients died: 12 during the first year of the follow-up, and 4 at 21st, 34th, 37th and 82nd month of observation. Five patients died from neoplastic cachexia, 4 from hypokinetic cardiopathy, 3 from hemorrhagic complications, 2 from pneumonia and one from unknown cause. Mean patient survival after presentation was 18.1 +/- 20.7 months.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7634543

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  11 in total

1.  Daratumumab in light chain deposition disease: rapid and profound hematologic response preserves kidney function.

Authors:  Paolo Milani; Marco Basset; Paola Curci; Andrea Foli; Rita Rizzi; Mario Nuvolone; Raffaella Guido; Loreto Gesualdo; Giorgina Specchia; Giampaolo Merlini; Giovanni Palladini
Journal:  Blood Adv       Date:  2020-04-14

2.  Natural history and outcome of light chain deposition disease.

Authors:  Rabya H Sayed; Ashutosh D Wechalekar; Janet A Gilbertson; Paul Bass; Shameem Mahmood; Sajitha Sachchithanantham; Marianna Fontana; Ketna Patel; Carol J Whelan; Helen J Lachmann; Philip N Hawkins; Julian D Gillmore
Journal:  Blood       Date:  2015-09-21       Impact factor: 22.113

3.  Light Chain Deposition Disease: A Morphological Case Report.

Authors:  Hristo Popov; George S Stoyanov; Peter Ghenev
Journal:  Cureus       Date:  2022-06-27

Review 4.  Paraprotein-Related Kidney Disease: Glomerular Diseases Associated with Paraproteinemias.

Authors:  Shveta S Motwani; Leal Herlitz; Divya Monga; Kenar D Jhaveri; Albert Q Lam
Journal:  Clin J Am Soc Nephrol       Date:  2016-08-15       Impact factor: 8.237

5.  Primary cystic lung light chain deposition disease: a clinicopathologic entity derived from unmutated B cells with a stereotyped IGHV4-34/IGKV1 receptor.

Authors:  Magali Colombat; Hervé Mal; Christiane Copie-Bergman; Jacques Diebold; Diane Damotte; Patrice Callard; Michel Fournier; Jean-Pierre Farcet; Marc Stern; Marie-Hélène Delfau-Larue
Journal:  Blood       Date:  2008-05-15       Impact factor: 22.113

6.  Light chain deposition disease affecting the gastrointestinal tract in the setting of post-living donor kidney transplantation.

Authors:  Victor H Jimenez-Zepeda; Rajkumar Vajpeyi; Rohan John; Suzanne Trudel
Journal:  Int J Hematol       Date:  2012-05-10       Impact factor: 2.490

Review 7.  Management of renal dysfunction in multiple myeloma.

Authors:  Sandeep R Pandit; David H Vesole
Journal:  Curr Treat Options Oncol       Date:  2003-06

8.  Atypical case of AL amyloidosis with urinary erythrocyte casts.

Authors:  Orfeas Liangos; Maike Buettner-Herold; Markus Ketteler; Nicolaos E Madias
Journal:  Clin Nephrol Case Stud       Date:  2015-09-23

9.  The Role of Kidney Transplantation in Monoclonal Ig Deposition Disease.

Authors:  Avital Angel-Korman; Lauren Stern; Yoel Angel; Shayna Sarosiek; Hanni Menn-Josephy; Jean Francis; Sandeep Ghai; J Mark Sloan; Vaishali Sanchorawala; Andrea Havasi
Journal:  Kidney Int Rep       Date:  2020-03-09

10.  Primary cerebral low-grade B-cell lymphoma, monoclonal immunoglobulin deposition disease, cerebral light chain deposition disease and "aggregoma": an update on classification and diagnosis.

Authors:  Marco Skardelly; Georgios Pantazis; Sotirios Bisdas; Guenther C Feigl; Martin U Schuhmann; Marcos S Tatagiba; Rainer Ritz
Journal:  BMC Neurol       Date:  2013-08-15       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.